

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/186437 A1

(43) International Publication Date
23 September 2021 (23.09.2021)

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/137 (2006.01)
A61K 9/16 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/IL2021/050288

(22) International Filing Date:

16 March 2021 (16.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/989,913 16 March 2020 (16.03.2020) US
17/135,528 28 December 2020 (28.12.2020) US

(71) Applicant: NASUS PHARMA LTD. [IL/IL]; 29
Harakevet Street, Tel Aviv, 6618306 (IL).

(72) Inventors: TEMTSIN-KRAYZ, Galia; 23 Egoz Street,
7777112 Ashdod (IL). KAZHDAN, Pavel; 51 Israel
Hashaked Street, Yavne (IL).

(74) Agent: HACKMEY, Michal; Reinhold Cohn & Partners,
P.O.B. 13239, 6113102 Tel-Aviv (IL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: TREATMENT WITH POWDERED INTRANASAL EPINEPHRINE

(57) Abstract: Disclosed is a pharmaceutical composition in dry powder form for intranasal administration, comprising an anti-ana-
phylactic adrenergic receptor agonist in the form of dry powder for intranasal administration, the composition comprising solid particles
of the active agent in combination with at least one functional additive, and solid particles of an inert carrier.

WO 2021/186437 A1